REVIVA PHARMA HLDGS INC
RVPH
RVPH was delisted on the 13th of May, 2026.
21 hedge funds and large institutions have $39.6M invested in REVIVA PHARMA HLDGS INC in 2019 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
2% more capital invested
Capital invested by funds: $39M → $39.6M (+$651K)
0% more funds holding
Funds holding: 21 → 21 (0)
0.01% less ownership
Funds ownership: 2.33% → 2.31% (-0.01%)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MSU
Mizuho Securities USA
New York
|
+$284K |
| 2 |
KIM
Karpus Investment Management
Pittsford,
New York
|
+$225K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$141K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$12.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$1.18M |
| 2 |
BFM
Boothbay Fund Management
New York
|
-$670K |
| 3 |
Walleye Trading
New York
|
-$97.9K |
| 4 |
HIM
HGC Investment Management
Toronto,
Ontario, Canada
|
-$3K |
| 5 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$2.06K |
RVPH Hedge Fund Activity: Q3 2019 in Review
21 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in REVIVA PHARMA HLDGS INC (RVPH) for Q3 2019, worth a combined $39.6M — up 1.7% from $39M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new RVPH positions and 1 closed out — a net gain of 1 holder — while 4 added to existing stakes and 5 trimmed.
The largest buyer was Mizuho Securities USA, adding an estimated $284K. The largest seller was Panagora Asset Management, cutting an estimated $1.18M.
- 21 institutional investors held REVIVA PHARMA HLDGS INC (RVPH) as of Q3 2019, unchanged from Q2 2019.
- Funds reported $39.6M of REVIVA PHARMA HLDGS INC stock for Q3 2019, up 1.7% quarter-over-quarter.
- 2 funds opened new REVIVA PHARMA HLDGS INC positions in Q3 2019 and 1 closed out, a net change of +1 holder.
- The largest REVIVA PHARMA HLDGS INC buyer in Q3 2019 was Mizuho Securities USA, an estimated $284K added.
- The largest REVIVA PHARMA HLDGS INC seller in Q3 2019 was Panagora Asset Management, an estimated $1.18M sold.
Based on aggregated 13F filings for Q3 2019.